Efficacy and Safety Data from SunRISe-1

Results from CREST will be presented at an upcoming medical conference.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

9MW2821 was previously awarded a breakthrough therapy designation as a monotherapy for locally advanced or metastatic urothelial carcinoma.

“We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.

The NMPA’s approval was supported by data from the phase 3 EV-302 trial.

The J-code became effective on January 1, 2025.